Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer

No AccessJournal of Urology1 Mar 1992Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer Donald L. Lamm, Ad P.M. Van Der Meijden, Alvaro Morales, Stanley A. Brosman, William J. Catalona, Harry W. Herr, Mark S. Soloway, Adolphe Steg, and Frans M.J. Debruyne Donald L. LammDonald L. Lamm More articles by this author , Ad P.M. Van Der MeijdenAd P.M. Van Der Meijden More articles by this author , Alvaro MoralesAlvaro Morales More articles by this author , Stanley A. BrosmanStanley A. Brosman More articles by this author , William J. CatalonaWilliam J. Catalona More articles by this author , Harry W. HerrHarry W. Herr More articles by this author , Mark S. SolowayMark S. Soloway More articles by this author , Adolphe StegAdolphe Steg More articles by this author , and Frans M.J. DebruyneFrans M.J. Debruyne More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)37316-0AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Intravesical therapy with bacillus Calmette-Guerin (BCG) has proved to be more effective in the prophylaxis and treatment of superficial bladder tumors and carcinoma in situ than most chemotherapeutic agents. Compared to intravesical chemotherapy, instillations with BCG provoke more local and systemic reactions. In addition to the commonly induced granulomatous inflammatory changes in the bladder, which produce irritative symptoms, this therapy may cause systemic side effects varying from mild malaise and fever to, in rare instances, life-threatening or fatal sepsis. We report the incidence and varieties of toxicities in 2,602 patients treated with intravesical BCG. Side effects are classified according to local and systemic toxicity. Treatment options vary according to the severity of toxicity from delaying or withholding instillations to treatment with antituberculous drugs for up to 6 months. In general, 95% of the patients have no serious side effects. Recognition of risk factors, particularly traumatic catheterization or concurrent cystitis, that result in systemic BCG absorption, as well as the prompt and appropriate treatment of early side effects should significantly decrease the incidence of severe toxicity. © 1992 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByRose A, El-Leithy T, Dorp F, Zakaria A, Eisenhardt A, Tschirdewahn S and Rübben H (2018) Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation StudyJournal of Urology, VOL. 194, NO. 4, (939-943), Online publication date: 1-Oct-2015.Falke J, Lammers R, Arentsen H, Ravic M, Pozzi R, Cornel E, Vergunst H, de Reijke T and Witjes J (2018) Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 189, NO. 6, (2077-2082), Online publication date: 1-Jun-2013.Pan C, Shen Z and Ding G (2018) The Effect of Intravesical Instillation of Antifibrinolytic Agents on Bacillus Calmette-Guerin Treatment of Superficial Bladder Cancer: A Pilot StudyJournal of Urology, VOL. 179, NO. 4, (1307-1312), Online publication date: 1-Apr-2008.Koya M, Simon M and Soloway M (2018) Complications of Intravesical Therapy for Urothelial Cancer of the BladderJournal of Urology, VOL. 175, NO. 6, (2004-2010), Online publication date: 1-Jun-2006.Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L and Rischmann P (2018) The Effect of Ofloxacin on Bacillus Calmette-Guerin Induced Toxicity in Patients With Superficial Bladder Cancer: Results of a Randomized, Prospective, Double-Blind, Placebo Controlled, Multicenter StudyJournal of Urology, VOL. 176, NO. 3, (935-939), Online publication date: 1-Sep-2006.ELSÄSSER-BEILE U, LEIBER C, WOLF P, LUCHT M, MENGS U and WETTERAUER U (2018) ADJUVANT INTRAVESICAL TREATMENT OF SUPERFICIAL BLADDER CANCER WITH A STANDARDIZED MISTLETOE EXTRACTJournal of Urology, VOL. 174, NO. 1, (76-79), Online publication date: 1-Jul-2005.BİLEN C, İNCİ K, ERKAN İ and ÖZEN H (2018) The Predictive Value Of Purified Protein Derivative Results On Complications And Prognosis In Patients With Bladder Cancer Treated With Bacillus Calmette-GuerinJournal of Urology, VOL. 169, NO. 5, (1702-1705), Online publication date: 1-May-2003.Goebell P, Otto T, Suhr J and Rübben H (2018) Evaluation of an Unconventional Treatment Modality with Mistletoe Lectin to Prevent Recurrence of Superficial Bladder Cancer: A Randomized Phase ii TrialJournal of Urology, VOL. 168, NO. 1, (72-75), Online publication date: 1-Jul-2002.SYLVESTER R, van der MEIJDEN A and LAMM D (2018) Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, VOL. 168, NO. 5, (1964-1970), Online publication date: 1-Nov-2002.Durek C, Jurczok A, Werner H, Jocham D and Böhle A (2018) Optimal Treatment of Systemic Bacillus Calmette-Guerin Infection: Investigations in an Animal ModelJournal of Urology, VOL. 168, NO. 2, (826-831), Online publication date: 1-Aug-2002.MORALES A, CHIN J and RAMSEY E (2018) MYCOBACTERIAL CELL WALL EXTRACT FOR TREATMENT OF CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 166, NO. 5, (1633-1638), Online publication date: 1-Nov-2001.VAN DER MEIJDEN A, BRAUSI M, ZAMBON V, KIRKELS W, DE BALINCOURT C and SYLVESTER R (2018) INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIALJournal of Urology, VOL. 166, NO. 2, (476-481), Online publication date: 1-Aug-2001.DUREK C, RICHTER E, BASTECK A, RÜSCH-GERDES S, GERDES J, JOCHAM D and BÖHLE A (2018) THE FATE OF BACILLUS CALMETTE-GUERIN AFTER INTRAVESICAL INSTILLATIONJournal of Urology, VOL. 165, NO. 5, (1765-1768), Online publication date: 1-May-2001.KIM J and STEINBERG G (2018) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 165, NO. 3, (745-756), Online publication date: 1-Mar-2001.KIM I, SMITH C, OLIVERO J and LAPIN S (2018) BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON DIALYSISJournal of Urology, VOL. 163, NO. 1, (237-237), Online publication date: 1-Jan-2000.DUREK C, RÜSCH-GERDES S, JOCHAM D and BÖHLE A (2018) INTERFERENCE OF MODERN ANTIBACTERIALS WITH BACILLUS CALMETTE-GUERIN VIABILITYJournal of Urology, VOL. 162, NO. 6, (1959-1962), Online publication date: 1-Dec-1999.ALI-EL-DEIN B, NABEEH A, ISMAIL E and GHONEIM M (2018) SEQUENTIAL BACILLUS CALMETTE-GUERIN AND EPIRUBICIN VERSUS BACILLUS CALMETTE-GUERIN ALONE FOR SUPERFICIAL BLADDER TUMORS: A RANDOMIZED PROSPECTIVE STUDYJournal of Urology, VOL. 162, NO. 2, (339-342), Online publication date: 1-Aug-1999.Siskron T, Venable D, Gonzalez E and Eastham J (2018) Granulomatous Mass in a NonRefluxing Renal Unit After Bacillus Calmette-Guerin Therapy for Bladder CancerJournal of Urology, VOL. 158, NO. 3, (882-883), Online publication date: 1-Sep-1997.Vegt P, van der Meijden A, Sylvester R, Brausi M, Holtl W and de Balincourt C (2018) Does Isoniazid Reduce Side Effects of Intravesical Bacillus Calmette-Guerin Therapy in Superficial Bladder Cancer? Interim Results of European Organization for Research and Treatment of Cancer Protocol 30911Journal of Urology, VOL. 157, NO. 4, (1246-1249), Online publication date: 1-Apr-1997.Zlotta A, Drowart A, Van Vooren J, de Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman C and Huygen K (2018) Evolution and Clinical Significance of the T Cell Proliferative and Cytokine Response Directed Against the Fibronectin Binding Antigen 85 Complex of Bacillus Calmette-Guerin During Intravesical Treatment of Superficial Bladder CancerJournal of Urology, VOL. 157, NO. 2, (492-498), Online publication date: 1-Feb-1997.Tuncer S, Tekin M, Ozen H, Bilen C, Unal S and Remzi D (2018) DETECTION OF BACILLUS CALMETTE-GUERIN IN THE BLOOD BY THE POLYMERASE CHAIN REACTION METHOD OF TREATED BLADDER CANCER PATIENTSJournal of Urology, VOL. 158, NO. 6, (2109-2112), Online publication date: 1-Dec-1997.Chin J, Kadhim S, Batislam E, Karlik S, Garcia B, Nickel C and Morales A (2018) Mycobacterium Cell Wall: An Alternative to Intravesical Bacillus Calmette Guerin (BCG) Therapy in Orthotopic Murine Bladder CancerJournal of Urology, VOL. 156, NO. 3, (1189-1193), Online publication date: 1-Sep-1996.Schnapp D, Weiss G and Smith A (2018) Fever Following Intracavitary Bacillus Calmette-Guerin Therapy for Upper Tract Transitional Cell CarcinomaJournal of Urology, VOL. 156, NO. 2, (386-388), Online publication date: 1-Aug-1996.Rintala E, Jauhiainen K, Kaasinen E, Nurmi M and Alfthan O (2018) Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Prophylaxis For Recurrent Papillary (Stages Ta to T1) Superficial Bladder CancerJournal of Urology, VOL. 156, NO. 1, (56-60), Online publication date: 1-Jul-1996.Bohle A, Rusch-Gerdes S, Ulmer A, Braasch H and Jocham D (2018) The Effect of Lubricants on Viability of Bacillus Calmette-Guerin for Intravesical Immunotherapy Against Bladder CarcinomaJournal of Urology, VOL. 155, NO. 6, (1892-1896), Online publication date: 1-Jun-1996.Luftenegger W, Ackermann D, Futterlieb A, Kraft R, Minder C, Nadelhaft P and Studer U (2018) Intravesical Versus Intravesical Plus Intradermal Bacillus Calmette-Guerin: A Prospective Randomized Study In Patient With Recurrent Superficial Bladder TumorsJournal of Urology, VOL. 155, NO. 2, (483-487), Online publication date: 1-Feb-1996.Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E and Alfthan O (2018) Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Therapy for Carcinoma in Situ of the BladderJournal of Urology, VOL. 154, NO. 6, (2050-2053), Online publication date: 1-Dec-1995.Niku S, Stein P, Scherz H and Parsons C (2018) A New Method for Cytodestruction of Bladder Epithelium Using Protamine Sulfate and UreaJournal of Urology, VOL. 152, NO. 3, (1025-1028), Online publication date: 1-Sep-1994.Bellman G, Sweetser P and Smith A (2018) Complications of Intracavitary Bacillus Calmette-Guerin After Percutaneous Resection of Upper Tract Transitional Cell CarcinomaJournal of Urology, VOL. 151, NO. 1, (13-15), Online publication date: 1-Jan-1994.Reinert K and Sybrecht G (2018) T Helper Cell Alveolitis after Bacillus Calmette-Guerin Immunotherapy For Superficial Bladder TumorJournal of Urology, VOL. 151, NO. 6, (1634-1635), Online publication date: 1-Jun-1994.Sharpe J, Duffy G and Chin J (2018) Intrarenal Bacillus Calmette-Guerin Therapy for Upper Urinary Tract Carcinoma in SituJournal of Urology, VOL. 149, NO. 3, (457-459), Online publication date: 1-Mar-1993.Soloway M (2018) Editorial CommentJournal of Urology, VOL. 149, NO. 3, (459-460), Online publication date: 1-Mar-1993.Fishman J, Walton D, Flynn N, Benson D and Devere White R (2018) Tuberculous Spondylitis as A Complication of Intravesical Bacillus Calmette-Guerin TherapyJournal of Urology, VOL. 149, NO. 3, (584-587), Online publication date: 1-Mar-1993.Morales A, Nickel J and Wilson J (2018) Dose-Response of Bacillus Calmette-Guerin in the Treatment of Superficial Bladder CancerJournal of Urology, VOL. 147, NO. 5, (1256-1258), Online publication date: 1-May-1992.Herr H (2018) Editorial CommentsJournal of Urology, VOL. 147, NO. 5, (1258-1258), Online publication date: 1-May-1992.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 147, NO. 5, (1258-1258), Online publication date: 1-May-1992. Volume 147Issue 3 Part 1March 1992Page: 596-600 Advertisement Copyright & Permissions© 1992 by The American Urological Association Education and Research, Inc.Keywordscarcinoma in situBCG vaccinebladder neoplasmsMetricsAuthor Information Donald L. Lamm More articles by this author Ad P.M. Van Der Meijden More articles by this author Alvaro Morales More articles by this author Stanley A. Brosman More articles by this author William J. Catalona More articles by this author Harry W. Herr More articles by this author Mark S. Soloway More articles by this author Adolphe Steg More articles by this author Frans M.J. Debruyne More articles by this author Expand All Advertisement PDF DownloadLoading ...